SuperGen Reports 2009 Third Quarter Financial Results

SUPERGEN, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited)         Three months ended Nine months ended September 30, September 30,   2009     2008     2009     2008     Revenues: Royalty revenue $ 10,357   $ 10,209 ...
Click here to read the whole Article (external link)

SuperGen Earnings Call scheduled for 4:30 pm ET today

Call DetailsSuperGen Earnings Conference Call (Q3 2009)Mon, Oct 26, 2009, 4:30 pm EasternAbout SuperGen (NasdaqGM:SUPG)SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. The company licensed its new drug application approved product, Dacogen for the treatment of patients with myelodysplastic syndromes. It primarily focuses on developing MP-470, a DNA repair suppressor; SGI-1776, a PIM kinase inhibitor; MP-529, an Aurora kinase inhibitor; SGI-110, a DNMT1 inhibitor; and SGI-1252, a JAK2 inhibitor. SuperGen also has an approved product, Mitozytrex for the treatment of solid tumors. In addition, the company is developing Orathecin, a Phase III clinical trial product for the treatment of solid tumors; Partaject busulfan, a Phase I/II clinical trial product for neoplastic meningitis/bone marrow transplant; Partaject Orathecin, a non-clinical stage product for the treatment of solid tumors; and CZ 112, a Phase I clinical trial product for the treatment of solid tumors. It is also developing Cremophor-free paclitaxel, a non-clinical stage product for the treatment of solid tumors; Avicine, a therapeutic vaccine for the treatment of cancer, which is in Phase II trial; VEGF, a non-clinical stage product for the treatment of anti-angiogenesis; PZG, a Phase II clinical trial product for the treatment of type II diabetes; and AM454, a phosphocholine derivative, which is in non-clinical stage for obesity/diabetes. The company sells its products to clinics, hospitals, hospital buying groups, drug distributors, and wholesalers in the United States and Europe. SuperGen was founded in 1991 and is based in Dublin, California.More Info:Quote |Chart...
Click here to read the whole Article (external link)

SuperGen, Inc.Q3 2009 Earnings Call Transcript

SuperGen, Inc. (SUPG) Q3 2009 Earnings Call October 26, 2009 4:30 pm ET Executives Timothy Enns - SVP, Corporate Communications and Business Development Dr. James Manuso - President and Chief Executive Officer Michael Molkentin - Chief Financial Officer Dr. Mohammad Azab - Chief Medical Officer Dr. Michael McCullar - Vice President, Strategy and Discovery Operations Analysts Joe Pantginis - Merriman Curhan Ford & Co. Boris Peaker - Rodman & Renshaw Robin Davidson - Edison Investment Research Presentation Operator Good day, ladies and gentlemen, and welcome to the third quarter 2009 SuperGen earnings conference call. My name is Regina, and I will be your operator for today. (Operator Instructions) I would now like to turn the conference over to your host for today, Timothy Enns, Senior Vice President of Corporate Communications and Business Development. Please proceed, sir. Timothy Enns Thank you, Operator. Good afternoon and thank you for joining us today on SuperGen's 2009 third quarter conference call. With me today are Dr. James Manuso, President and Chief Executive Officer, Michael Molkentin, Chief Financial Officer, Dr. Mohammad Azab, Chief Medical Officer, and Michael McCullar, Vice President, Strategy and Discovery Operations. In a few moments Jim Manuso and Michael Molkentin will deliver remarks on the recently announced discovery and development deal with GlaxoSmithKline or GSK, our 2009 third quarter financial results, and provide a summary of our business outlook. After our prepared comments, we will open the line for questions. Earlier today we issued two press releases. One release announced the transaction wit...
Click here to read the whole Article (external link)

SuperGen to Present at Merriman Curhan Ford Investor Summit on November 10, 2009

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

SUPERGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,

Item 1.01 Entry into a Material Definitive Agreement. On October 22, 2009, SuperGen, Inc. (the "Company") entered into the following material agreements with Smithkline Beecham Corporation, doing business as GlaxoSmithKline ("GSK"): (1) a Commercial Research and License Agreement (the "License Agreement") and (2) a Common Stock Purchase Agreement (the "Purchase Agreement"). Both the License Agreement and the Purchase Agreement were effective as of October 22, 2009. Pursuant to the terms of the License Agreement, the Company and GSK will collaborate over a period of five years to discover and develop specific epigenetic therapeutics. At the end of the research term, or earlier if GSK elects, GSK may exercise its option to license from the Company the compounds that are the result of the joint research effort, in order to continue the development and ultimately commercialize and sell the products worldwide. Within ten days of the effective date of the License Agreement, GSK will pay the Company an upfront sum of $2 million. In addition, GSK is obligated to make certain payments to the Company if and when the compounds reach specified developmental milestones, as well as payments to the Company if and when the compounds that GSK has licensed achieve certain regulatory milestones. The License Agreement further provides that, if the licensed compounds derived from the joint research team become products, GSK will pay the Company sales milestone payments as well as royalties on annual net sales of such products. The royalties will be paid on a country-by-country and product-by-product basis. The License Agreement contains customary representations and warranties by both parties, as well as mutual indemnification rights with respect to, among other matters, development or commercialization of the products derived from the joint research term. Pursuant to the Purchase Agreement, on the effective date, the Company issued and sold 990,099 s...
Click here to read the whole Article (external link)

SuperGen Presentations at AACR-NCI-EORTC

MP-470: The tyrosine kinase inhibitor MP470 inhibits RAD51-mediated homologous recombination and increases tumor cell radio- and chemosensitivity Abstract A122, Monday Nov 16, 12:30 – 2:30 pm EST   SGI-110: In vivo activity of SGI-110, a novel hypomethylating agent for treatment in hematology and solid malignancies Abstract A190, Monday Nov 16, 12:30 – 2:30 pm EST   MP-470: A self-emulsifying lipid suspension formulation enhances oral bioavailability of MP-470 in a randomized two-way crossover study in healthy male subjects Abstract B209, Tuesday Nov 17, 12:30 – 2:30 pm EST   SGI-1776: The novel PIM kinase inhibitor SGI-1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma Abstract B272, Tuesday Nov 17, 12:30 – 2:30 pm EST   ETK/BMX: Mechanistic, functional and in vivo efficacy of inhibiting ETK/BMX in cancer models Abstract B263, Tuesday Nov 17, 12:30 – 2:30 pm...
Click here to read the whole Article (external link)

SuperGen to Present at Lazard Healthcare Conference on November 18, 2009

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

SUPERGEN INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion together with our condensed consolidated financial statements and related notes included elsewhere in this report. The results discussed below are not necessarily indicative of the results to be expected in any future periods. Our disclosure and analysis in this section of the report also contain forward-looking statements. When we use the words "anticipate," "estimate," "project," "intend," "expect," "plan," "believe," "should," "likely" and similar expressions, we are making forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. In particular, these statements include statements such as: our estimates about becoming profitable; the percentage of royalties we expect to earn on Dacogen sales under our agreement with MGI/Eisai; our forecasts regarding our research and development expenses; our expectations about the joint development program with GSK; and our statements regarding the sufficiency of our cash to meet our operating needs. Our actual results could differ materially from those predicted in the forward-looking statements as a result of risks and uncertainties including, but not limited to, delays and risks associated with conducting and managing our clinical trials; developing products and obtaining regulatory approval; ability to establish and maintain collaborative relationships; competition; ability to obtain funding; ability to protect our intellectual property; our dependence on third party suppliers; risks associated with the hiring and loss of key personnel; adverse changes in the specific markets for our products; and our ability to launch and commercialize our products. Certain unknown or immaterial risks and uncertainties can also affect our forward-looking statements. Consequentl...
Click here to read the whole Article (external link)

SUPERGEN INC Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue10,357  6,012  12,913  11,942  Cost of Revenue -   -   -   -  Gross Profit10,357  6,012  12,913  11,942  Operating ExpensesResearch Development7,259  6,757  7,334  8,157  Selling General and Administrative2,440  1,984  2,225  2,259  Non Recurring500   -  (500)4,509  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss678  (2,729)3,854  (2,983)Income from Continuing OperationsTotal Other Income/Expenses Net672  188  270  384  Earnings Before Interest And Taxes830  (2,541)4,124  (2,599)Interest Expense -   -   -   -  Income Before Tax830  (2,541)4,124  (2,599)Income Tax Expense(3)(115)130  (6)Minority Interest -   -   -   -  Net Income From Continuing Ops833  (2,426)3,994  (2,593)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   -   ...
Click here to read the whole Article (external link)